EGFR and familial pancreatic carcinoma: We also tested the effect of enzastaurin treatment on tumour growth in other EGFR-expressing cancer cell lines, including SKLU-1 and GLC-82 (NSCL cancer) and PACA44, PANC1 and HPAF (pancreatic cancer cells).